Association of Devbhumi Pharma Industries hosts meet on Pharmacopoeia Standards and Quality Considerations

1 Star2 Stars3 Stars4 Stars5 Stars (No Ratings Yet)
Medlarge Pharma News, Featured, Research
NEET aspirant

The Association of Devbhumi Pharma Industries, Uttarakhand, held Interactive Meet on Saturday. The meet brought together pharma professionals managing quality, regulatory and manufacturing functions to discuss vital topics related to pharmacopoeia standards, quality considerations, and the revision of Schedule M.

The event was graced by Dr. Rajeev Singh Raghuvanshi, Secretary cum Scientific Director at the Indian Pharmacopoeia Commission (IPC) and Drug Controller General of India (DCGI), Central Drugs Standard Control Organization (CDSCO) as the Chief Guest and Mr. Tajber Singh, Drug Controlling and Licensing Authority, Uttarakhand as the Guest of Honor. Mr. Sandeep Jain, Chairman of ADPI and Joint Director of Akums Drugs & Pharmaceuticals Limited, facilitated the event and welcomed the dignitaries and delegates for their gracious presence.

Dr. Raghuvanshi lauded the efforts of Uttarakhand pharma manufacturers and acknowledged the changing global perspective in the pharmaceutical industry. He highlighted the importance of updating the industry in collaboration with global regulators. Dr. Raghuvanshi emphasised the critical aspects of pharmacopoeia standards and quality considerations, stressing that it is the industry’s responsibility to execute the provisions of IPC 2022 and timely implementation of the revised Schedule M notification. He underscored that quality should never be compromised for cost and called for active participation from the pharmaceutical community to ensure India as “Quality Pharmacy of the World”.

Mr. Tajber Singh, added regional perspectives and regulatory updates to the discussions. He highlighted DCGI’s objective to ensure the highest quality drugs with utmost standards, ensuring minimal disruption to stakeholders. However, he strongly emphasised there will be no compromise of quality manufacturing and each manufacturer must ensure 100% compliance.

Mr. Sandeep Jain emphasised the importance of the pharmaceutical industry and indirectly contributed to employment opportunities. He proudly lauded the pharmaceutical industry’s noble role during the Covid-19 pandemic, ensuring stable pricing and providing essential medicines. He reiterated the industry’s commitment to delivering competitive prices and top-quality products and commended the industry stakeholders for their significant contributions to corporate social responsibility.

Mr. Pramod Kalani Vice Chairman ADPI, in his vote of thanks, ensured that Uttrakhand manufactures will uphold the image of our country as Quality manufacturers of the world. He thanked both Dr Raghuvanshi and Mr. Tajbeer Singh for their time and guidance and presence for the entire session.

This interactive meet proved to be an important platform for discussing pharmacopoeia standards, quality considerations, and the revision of Schedule M, promoting alignment with global standards and best manufacturing practices. The question answer session by CDSCO and IPC team clarified the points put forward by delegates and gave the required guidance on implementation of IP 2022.

Akums Drugs & Pharmaceuticals Limited as the sponsor extended generous support and made it possible to bring together key stakeholders and experts to exchange knowledge and insights on this crucial subject.